Experimental studies of the antitumor activity of amygdalin MF (NSC-15780) alone and in combination with beta-glucosidase (NSC-128056).
Amygdalin MF was evaluated alone and in combination with an activating agent, beta-glucosidase, against three transplantable rodent tumors; Ridgway osteogenic sarcoma, Lewis lung carcinoma, and P388 leukemia. In dose-response studies up to the LD20 in normal mice, amygdalin MF alone did not demonstrate significant antitumor activity against any of these three tumor systems. Similarly, at doses not exceeding the LD10 in normal mice, amygdalin MF plus beta-glucosidase did not demonstrate antitumour activity against any of these three tumor systems. Potentiation of the lethal toxicity of amygdalin MF by beta-glucosidase was observed in all studies where the two agents were given in simultaneous combination.
D000678:Amygdalin / Q000627:therapeutic use*; D000818:Animals; D004359:Drug Therapy, Combination; D005959:Glucosidases / Q000627:therapeutic use*; D007942:Leukemia, Experimental / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D009570:Nitriles / Q000627:therapeutic use*; D012516:Osteosarcoma / Q000188:drug therapy; D012513:Sarcoma, Experimental / Q000188:drug therapy; D013997:Time Factors
D009570:Nitriles; D000678:Amygdalin; D005959:Glucosidases